Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2022 | 1 |
2023 | 2 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study.
BMC Med. 2022 Nov 23;20(1):453. doi: 10.1186/s12916-022-02646-0.
BMC Med. 2022.
PMID: 36424628
Free PMC article.
Clinical Trial.
Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study.
Shi Y, Zhou J, Zhao Y, Zhu B, Zhang L, Li X, Fang J, Shi J, Zhuang Z, Yang S, Wang D, Yu H, Zhang L, Zheng R, Greco M, Wang T.
Shi Y, et al.
BMC Med. 2023 Jan 8;21(1):11. doi: 10.1186/s12916-022-02692-8.
BMC Med. 2023.
PMID: 36617560
Free PMC article.
Clinical Trial.
Item in Clipboard
Incidence, survival comparison, and novel prognostic evaluation approaches for stage iii-iv pulmonary large cell neuroendocrine carcinoma and small cell lung cancer.
Huang L, Feng Y, Xie T, Zhu H, Tang L, Shi Y.
Huang L, et al.
BMC Cancer. 2023 Apr 5;23(1):312. doi: 10.1186/s12885-023-10797-3.
BMC Cancer. 2023.
PMID: 37020179
Free PMC article.
Item in Clipboard
Cite
Cite